首页> 外文期刊>Pharmacogenetics and genomics >Cis -acting regulatory elements regulating CYP3A4 transcription in human liver
【24h】

Cis -acting regulatory elements regulating CYP3A4 transcription in human liver

机译:CIS -ACTING调节元素调节人肝中CYP3A4转录

获取原文
获取原文并翻译 | 示例
           

摘要

Supplemental Digital Content is available in the text. The CYP3A4 enzyme is the most abundant drug-metabolizing enzyme in the liver, metabolizing ~50% of commonly used medications. CYP3A4 displays large interperson variability in expression and enzyme activity with unknown causes. This study aims to identify cis -acting regulatory elements controlling the transcription of CYP3A4 , using chromatin conformation capture (4C and 3C assays), chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR), clustered regularly interspaced short palindromic repeats (CRISPR)-mediated deletions of genomic regions and reporter gene assays in primary culture human hepatocytes and hepatic cell lines. 4C assays identified four regions (R1–R4) interacting with the CYP3A4 promoter, one of which overlaps with the previously identified upstream enhancers CLEM4/XREM (R2) while the other three are novel. ChIP-qPCR, reporter gene assays and CRISPR-mediated deletion experiments indicate regulatory roles for both R2 and R4. Interestingly, the deletion of R4 increased CYP3A4 while decreasing CYP3A43 expression, possibly due to competitive domain–domain interactions within the CYP3A cluster, supported by deletion of R4 increasing interaction between the CYP3A4 promoter and R2. We also identified a single nucleotide polymorphism rs62471956 within R4, with the variant allele A having increased transcriptional activity in a reporter gene assay. The rs62471956 A allele is associated with higher CYP3A43 expression and lower CYP3A4 expression in a cohort of 136 liver samples, further supporting the opposing effects of R4 on CYP3A4 and CYP3A43 . rs62471956 is in complete linkage disequilibrium with CYP3A4*22 , potentially contributing to reduced expression of CYP3A4*22 . These results validate previously identified enhancers (CLEM4 and XREM) of CYP3A4 and demonstrate additional regulatory mechanisms underlying CYP3A4 transcriptional control via competitive domain–domain interactions within the CYP3A cluster.
机译:文本中提供了补充数字内容。CYP3A4酶是肝脏中最丰富的药物代谢酶,代谢约50%的常用药物。CYP3A4在表达和酶活性方面表现出巨大的人际差异,原因不明。本研究旨在通过染色质构象捕获(4C和3C分析)、染色质免疫沉淀和定量PCR(芯片qPCR)鉴定控制CYP3A4转录的顺式作用调节元件,在原代培养的人肝细胞和肝细胞系中,聚集的规则间隔短回文重复序列(CRISPR)介导的基因组区域缺失和报告基因检测。4C分析确定了四个与CYP3A4启动子相互作用的区域(R1–R4),其中一个与先前确定的上游增强子CLEM4/XREM(R2)重叠,而其他三个是新的。芯片qPCR、报告基因分析和CRISPR介导的缺失实验表明R2和R4都具有调节作用。有趣的是,R4的缺失增加了CYP3A4的表达,同时降低了CYP3A4的表达,这可能是由于CYP3A簇内的竞争性结构域相互作用,R4的缺失增加了CYP3A4启动子和R2之间的相互作用。我们还发现R4中存在单核苷酸多态性rs62471956,在报告基因分析中,变异等位基因a的转录活性增加。在一组136份肝脏样本中,rs62471956 A等位基因与CYP3A4高表达和CYP3A4低表达相关,进一步支持R4对CYP3A4和CYP3A4的相反作用。rs62471956与CYP3A4*22处于完全连锁不平衡状态,可能导致CYP3A4*22表达降低。这些结果验证了之前发现的CYP3A4增强子(CLEM4和XREM),并通过CYP3A簇内的竞争性结构域-结构域相互作用证明了CYP3A4转录控制的其他调节机制。

著录项

  • 来源
    《Pharmacogenetics and genomics》 |2020年第5期|共10页
  • 作者

    Joseph M. Collins; Danxin Wang;

  • 作者单位

    Department of Pharmacotherapy and Translational Research College of Pharmacy Center for;

    Department of Pharmacotherapy and Translational Research College of Pharmacy Center for;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号